CL
ITCI

CSS LLC’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

CSS LLC’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,000
Closed -$1.11M – 932
2022
Q4 		$1.11M Buy
21,000
+4,000
+24% +$200K 0.06% 241
2022
Q3 		$791K Sell
17,000
-8,600
-34% -$449K 0.04% 402
2022
Q2 		$1.46M Buy
25,600
+5,000
+24% +$283K 0.06% 353
2022
Q1 		$1.26M Sell
20,600
-29,000
-58% -$1.51M 0.05% 374
2021
Q4 		$2.6M Sell
49,600
-24,900
-33% -$1.05M 0.09% 200
2021
Q3 		$2.78M Sell
74,500
-47,000
-39% -$1.63M 0.12% 177
2021
Q2 		$4.96M Buy
121,500
+79,400
+189% +$2.93M 0.21% 98
2021
Q1 		$1.43M Buy
42,100
+29,100
+224% +$1.01M 0.06% 298
2020
Q4 		$414K Buy
13,000
+12,700
+4,233% +$334K 0.02% 501
2020
Q3 		$8K Sell
300
-29,700
-99% -$678K ﹤0.01% 779
2020
Q2 		$770K Buy
+30,000
New +$607K 0.04% 314
2020
Q1 		– Sell
-65,900
Closed -$2.26M – 783
2019
Q4 		$2.26M Buy
+65,900
New +$791K 0.13% 144

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

CSS LLC's ITCI Position: Q2 2025 in Review

CSS LLC sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 28,904 shares — an estimated $3.81M sold.

CSS LLC first reported a position in ITCI in Q4 2019 and held it in 14 quarters. The position peaked at $3.81M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • CSS LLC reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • CSS LLC sold 28,904 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.81M.
  • CSS LLC first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 14 quarters.
  • CSS LLC's Intra-Cellular Therapies Inc. position peaked at $3.81M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on CSS LLC's 13F filing for Q2 2025, filed 14 Aug 2025.